Fusion Antibodies PLC (FAB) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.792x

Based on the latest financial reports, Fusion Antibodies PLC (FAB) has a cash flow conversion efficiency ratio of -0.792x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-575.00K ≈ $-69.96 USD) by net assets (GBX726.00K ≈ $88.33 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Fusion Antibodies PLC (FAB) balance sheet quality index to measure how much of total assets are equity-financed.

Fusion Antibodies PLC - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how Fusion Antibodies PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check FAB operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

Fusion Antibodies PLC Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Fusion Antibodies PLC ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Lexington Gold Ltd LSE:LEX	0.000x
Vergnet PA:ALVER	0.178x
Fulcrum Metals PLC LSE:FMET	N/A
Prospex Energy PLC LSE:PXEN	-0.052x
Metrics in Balance NV PA:MLMIB	N/A
Tasty Plc LSE:TAST	-0.245x
genedrive plc LSE:GDR	-1.421x
CROSS RIVER VENTURES CORP F:C6R	0.553x

Annual Cash Flow Conversion Efficiency for Fusion Antibodies PLC (2015–2025)

The table below shows the annual cash flow conversion efficiency of Fusion Antibodies PLC from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Fusion Antibodies PLC.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-03-31	GBX669.00K ≈ $81.40	GBX-1.36 Million ≈ $-165.96	-2.039x	-106.65%
2024-03-31	GBX1.79 Million ≈ $218.16	GBX-1.77 Million ≈ $-215.24	-0.987x	+36.87%
2023-03-31	GBX1.12 Million ≈ $136.64	GBX-1.75 Million ≈ $-213.53	-1.563x	-1644.63%
2022-03-31	GBX3.68 Million ≈ $448.24	GBX-330.00K ≈ $-40.15	-0.090x	+63.06%
2021-03-31	GBX4.75 Million ≈ $577.57	GBX-1.15 Million ≈ $-140.04	-0.242x	-602.87%
2020-03-31	GBX4.81 Million ≈ $585.48	GBX-166.00K ≈ $-20.20	-0.034x	+83.18%
2019-03-31	GBX5.35 Million ≈ $651.44	GBX-1.10 Million ≈ $-133.64	-0.205x	-1847.36%
2018-03-31	GBX6.58 Million ≈ $800.00	GBX77.19K ≈ $9.39	0.012x	+153.59%
2017-03-31	GBX1.71 Million ≈ $207.56	GBX-37.37K ≈ $-4.55	-0.022x	-109.21%
2016-03-31	GBX1.46 Million ≈ $177.28	GBX346.57K ≈ $42.17	0.238x	+122.12%
2015-03-31	GBX169.29K ≈ $20.60	GBX-182.05K ≈ $-22.15	-1.075x	--

About Fusion Antibodies PLC

LSE:FAB UK Biotechnology

Market Cap

$145.20K

GBX1.19 Billion GBX

Market Cap Rank

#31264 Global

#1056 in UK

Share Price

GBX10.50

Change (1 day)

+0.00%

52-Week Range

GBX9.75 - GBX19.25

All Time High

GBX213.00